<?xml version="1.0" encoding="UTF-8"?>
<!-- Dublin Core rendering of 079b647b-b2e8-4b5b-ad36-9ee6b8df2ce8, generated by folio-assistant-core/scripts/dc-render.ts. Do not edit. -->
<metadata xmlns="https://litlfred.github.io/folio-assistant-core/v0/ns/dspace/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <dcterms:creator>Ahmed, A.A.</dcterms:creator>
  <dcterms:creator>Latoundji, S.</dcterms:creator>
  <dc:date>2014-06-17T08:09:43Z</dc:date> <!-- dc.date.accessioned -->
  <dcterms:available xsi:type="dcterms:W3CDTF">2014-06-17T08:09:43Z</dcterms:available>
  <dcterms:issued xsi:type="dcterms:W3CDTF" xml:lang="EN">2007-12-31</dcterms:issued>
  <dcterms:description xml:lang="EN">1274-1285</dcterms:description>
  <dcterms:abstract xml:lang="EN">A cross-sectional survey was conducted among 112 HIV positive patients who had received antiretroviral therapy for &gt; 3 months to assess the efficacy of treatment [viral load &lt; 400 copies/mL]. The median age at enrolment was 36 years, 90% of patients were at the AIDS stage and median CD4 rate was 118/mm[3]. Patients received a combined treatment of 2 NRTI +1 NNRTI [51%], 3 NRTI [45%] and 2 NRTI+1 PI [4%]. Virological efficacy was seen in 74% of the patients, irrespective of the prescribed protocol and the initial clinical and immunological profile. Mean improvements measured were 20% on the Karnofsky index [KI], 2.1 kg/m[2] in body mass index and 82 cells/mm[3] in CD4. The prevalence of side effects was 84%. The predictors for treatment success were quality of care and KI &gt; 70%</dcterms:abstract>
  <dc:identifier xml:lang="EN">1020-3397</dc:identifier> <!-- dc.identifier.issn -->
  <dc:identifier xml:lang="EN">http://applications.emro.who.int/emhj/1306/13_6_2007_1274_1285.pdf</dc:identifier> <!-- dc.identifier.other -->
  <dcterms:identifier xsi:type="dcterms:URI">https://iris.who.int/handle/10665/117378</dcterms:identifier>
  <dcterms:language>Français</dcterms:language>
  <dcterms:language xsi:type="dcterms:RFC4646" xml:lang="EN">fr</dcterms:language>
  <dc:relation>EMHJ - Eastern Mediterranean Health Journal, 13 (6), 1274-1285, 2007</dc:relation> <!-- dc.relation.ispartofjournal -->
  <dcterms:subject xml:lang="EN">Anti-HIV Agents</dcterms:subject>
  <dcterms:subject xml:lang="EN">Anti-HIV Agents</dcterms:subject>
  <dcterms:subject xml:lang="EN">Body Mass Index</dcterms:subject>
  <dcterms:subject xml:lang="EN">Viral Load</dcterms:subject>
  <dcterms:subject xml:lang="EN">Case-Control Studies</dcterms:subject>
  <dcterms:subject xml:lang="EN">HIV Infections</dcterms:subject>
  <dcterms:subject xml:lang="EN">Treatment Outcome</dcterms:subject>
  <dcterms:subject xml:lang="EN">Pilot Projects</dcterms:subject>
  <dcterms:subject xml:lang="EN">Severity of Illness</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH" xml:lang="EN">Antiretroviral Therapy, Highly Active</dcterms:subject>
  <dcterms:title xml:lang="EN">[Pilot study of antiretroviral therapy in Djibouti]</dcterms:title>
</metadata>
